Novartis Operating Margin

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>NO</div>
NVS -- USA Stock  

Report: 21st of July 2020  

Novartis operating margin fundamental analysis lookup allows you to check this and other indicators for Novartis AG or any other equity instrument. You can also select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please continue to Equity Screeners to view more equity screening tools

Search Operating Margin

Novartis Operating Income is relatively stable at the moment as compared to the past year. Novartis reported last year Operating Income of 7.05 Billion. As of 07/10/2020, EBITDA Margin is likely to grow to 0.30, while Operating Expenses is likely to drop slightly above 25.3 B.

Novartis Operating Margin Analysis

Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
 2017 2019 (projected)
Book Value per Share31.2424.0
Asset Turnover0.330.37
Operating Margin 
Operating Income 
More About Operating Margin | All Equity Analysis

Current Novartis AG Operating Margin

33.89 %

Novartis Distress Driver Correlations

About Operating Margin

A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Compare to competition

Novartis Operating Margin Related Assessment

  EBITDA Margin

Based on the recorded statements Novartis AG has Operating Margin of 33.89%. This is 196.61% lower than that of the Healthcare sector, and significantly higher than that of Drug Manufacturers?General industry, The Operating Margin for all stocks is 715.06% lower than the firm.

Did you try this?

Run Premium Stories Now


Premium Stories

Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
All  Next Launch Module

NovartisCurrent Valuation Drivers

2014201520162017201820192020 (projected)
Average Assets125.82 B128.47 B130.84 B131.6 B139.32 B131.97 B140.55 B
Earnings before Tax11.76 B18.89 B7.83 B9.31 B13.91 B13.53 B13.89 B
Average Equity72.55 B73.91 B75.94 B74.5 B76.39 B67.04 B75.19 B
Enterprise Value236.13 B213.77 B190.17 B216.12 B218.53 B237.72 B236.29 B
Free Cash Flow11.33 B9.77 B9.77 B11.39 B13.12 B13.1 B13.51 B
Invested Capital52.66 B59.71 B62.39 B67.6 B60.82 B53.02 B60.88 B
Tangible Asset Value72.24 B66.17 B67.8 B71.33 B71.55 B63.06 B71.58 B
Working Capital10.59 B(863 M)2.72 B4.8 B5.96 B1.24 B1.27 B
Book Value per Share29.1732.1231.5231.2433.9224.029.65
Current Ratio1.161.390.961.
Debt to Equity Ratio0.70.770.710.740.851.131.06
Dividend Yield0.0310.0290.0280.0380.0260.140.15
Payout Ratio0.650.320.980.710.412.632.84
Price to Book Value3.182.682.312.692.533.953.57
Price to Sales Ratio4.
Sales per Share22.1121.0120.8318.2819.8921.0620.09
Capital Expenditure(2.56 B)(2.13 B)(1.7 B)(1.23 B)(1.15 B)(522 M)(563.21 M)

Novartis Fundamentals

About Novartis Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Novartis AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way. Please read more on our fundamental analysis page.
 2017 2018 2019 2020 (projected)
Current Assets28.21 B35.56 B29.5 B32.46 B
Total Assets133.08 B145.56 B118.37 B134.45 B

Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page